SUPERGEN INC
10-Q, EX-27.1, 2000-08-11
PHARMACEUTICAL PREPARATIONS
Previous: SUPERGEN INC, 10-Q, EX-10.1, 2000-08-11
Next: HEMASURE INC, 10-Q, 2000-08-11



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM SUPERGEN,
INC JUNE 30, 2000 CONSOLIDATED FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               JUN-30-2000
<CASH>                                         102,436
<SECURITIES>                                    18,699
<RECEIVABLES>                                    2,560
<ALLOWANCES>                                        10
<INVENTORY>                                      1,499
<CURRENT-ASSETS>                               128,206
<PP&E>                                           5,101
<DEPRECIATION>                                   1,684
<TOTAL-ASSETS>                                 175,534
<CURRENT-LIABILITIES>                            4,879
<BONDS>                                              0
                                0
                                          0
<COMMON>                                       271,494
<OTHER-SE>                                       3,819
<TOTAL-LIABILITY-AND-EQUITY>                   175,534
<SALES>                                          3,556
<TOTAL-REVENUES>                                 3,950
<CGS>                                              774
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                22,064
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                               (15,447)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (15,447)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (15,447)
<EPS-BASIC>                                     (0.51)
<EPS-DILUTED>                                   (0.51)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission